NMI Holdings CEO Adam Pollitzer sells $7.75m in common stock

Beta Bionics CEO Sean Saint recently sold 5,641 shares of the company's common stock on September 3, 2026. The transaction, conducted under a Rule 10b5-1 trading plan, generated approximately $113,258. The shares were sold at an average price of $20.0778 per share, with individual prices ranging from $20.00 to $20.1696. After the sale, Mr. Saint now directly owns 398,429 shares of Beta Bionics common stock.

On a separate note, Beta Bionics reported its second quarter 2026 financial results on September 3, 2026. The company experienced a substantial 38% increase in revenue, totaling $32 million for the quarter. However, Beta Bionics reported a wider-than-expected loss of 53 cents per share, surpassing the analysts' prediction of a 34-cent loss per share. Despite the revenue growth, the company's loss and loss per share figures raise concerns among investors.

In addition to the financial results, investment firm William Blair has initiated coverage on Beta Bionics with a Market Perform rating. Analyst Steven Lichtman praised the company's unique AID algorithm on the iLet insulin pump, noting that it requires minimal patient interaction. This advantage could potentially set Beta Bionics apart from its competitors.

Overall, these recent events provide investors with essential information about Beta Bionics' current financial situation and market positioning. The combination of revenue growth, a notable loss per share, and positive technological advancements creates a complex picture of the company's future prospects.